A policy evaluation found increasing naloxone prescribing without demonstrating a significant increase beyond the trajectory predicted from earlier data.
What the source reports
The study examined opioid recipients with risk indicators including benzodiazepine co-prescribing. It compared observed naloxone co-prescription after historical Military Health System policies with Bayesian time-series forecasts. Prescribing rose substantially over the study period, but adjusted comparisons did not show significant departures from forecasted rates.
Limits and uncertainty
A before-after rise alone does not isolate policy impact when a trend already exists. Results concern prescriptions, not whether naloxone was available, used correctly, or prevented an overdose. Institutional and purchased-care settings also differed.
Implications for forensic review
For an expert account of prevention, distinguish policy adoption, prescribing, possession, and clinical rescue. This study does not show that the policies had no value, but it does not prove they caused the observed growth. Individual opioid-benzodiazepine cases require their own risk assessment and prevention history.
Source and related reading
Source reviewed: Naloxone prescribing practices in the Military Health System before and after policy implementation (PMC8923585). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Hand-Holding and Conversation Were Added to Midazolam, Not Compared With Its Absence; Dominant Midazolam Sedation Was Associated With ICU Delirium in a Matched Cohort.
Leave a Reply